MOL Stock Overview
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Moleculin Biotech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.45 |
| 52 Week High | US$12.75 |
| 52 Week Low | US$3.99 |
| Beta | 1.85 |
| 1 Month Change | 0% |
| 3 Month Change | -2.27% |
| 1 Year Change | -37.68% |
| 3 Year Change | -84.86% |
| 5 Year Change | -94.96% |
| Change since IPO | -98.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| MOL | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -3.1% | 1.8% |
| 1Y | -37.7% | -22.4% | 2.2% |
Return vs Industry: MOL underperformed the German Biotechs industry which returned -21.1% over the past year.
Return vs Market: MOL underperformed the German Market which returned -0.3% over the past year.
Price Volatility
| MOL volatility | |
|---|---|
| MOL Average Weekly Movement | 14.6% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MOL's share price has been volatile over the past 3 months.
Volatility Over Time: MOL's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 18 | Wally Klemp | moleculin.com |
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers.
Moleculin Biotech, Inc. Fundamentals Summary
| MOL fundamental statistics | |
|---|---|
| Market cap | €9.71m |
| Earnings (TTM) | -€27.91m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs MOL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MOL income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$29.77m |
| Earnings | -US$29.77m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -13.36 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MOL perform over the long term?
See historical performance and comparison